<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00042666</url>
  </required_header>
  <id_info>
    <org_study_id>4849</org_study_id>
    <secondary_id>H6Q-MC-JCAI</secondary_id>
    <nct_id>NCT00042666</nct_id>
    <nct_alias>NCT00054080</nct_alias>
  </id_info>
  <brief_title>A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.</brief_title>
  <official_title>A Phase 2 Evaluation of Oral LY317615 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will measure the effectiveness and any side effects of LY317615 in patients with
      Diffuse large B-cell lymphoma (a sub-type of Non-Hodgkins Lymphoma).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimate the clinical response rate in patients with relapsed or refractory DLBCL who have received LY317615</measure>
    <time_frame>baseline to measured progressive disease</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimate objective response rate</measure>
    <time_frame>baseline to measured progressive disease</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure progression free survival</measure>
    <time_frame>baseline to measured progressive disease</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of overall response</measure>
    <time_frame>time of response to progressive disease</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate safety of LY317615 in this population</measure>
    <time_frame>every cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate population pharmacokinetics</measure>
    <time_frame>cycle 1, day 1 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess PKC beta expression by immunohistochemistry in readily assessable DLBCL tumors from patients</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">55</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY317615</intervention_name>
    <description>500 mg, oral, daily, up to six 28 day cycles</description>
    <other_name>enzastaurin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A diagnosis of recurrent or refractory Diffuse B-cell Non-Hodgkin's lymphoma.

          -  Adequate organ functions.

          -  Able to swallow capsules.

        Exclusion Criteria:

          -  More than 3 prior treatments for this disease.

          -  Serious heart problems.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2002</study_first_submitted>
  <study_first_submitted_qc>August 5, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2002</study_first_posted>
  <disposition_first_submitted>October 16, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>October 16, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 19, 2009</disposition_first_posted>
  <last_update_submitted>October 16, 2009</last_update_submitted>
  <last_update_submitted_qc>October 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2009</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Eli Lilly</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

